Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC88 plus Sintilimab in advanced solid tumors
NCT05804526Phase 2Recruiting
- Sponsor
- RemeGen
- Start
- Jul 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of misitatug blivedotin in solid tumor (advanced stage), sponsored by RemeGen. Started Jul 2023; status: recruiting.
02
Drugs
misitatug blivedotin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05804526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05804526.